硝氮烯类:比较药理学与拮抗剂作用综述
本综述检索EMBASE、Ovid MEDLINE(R)、APA PsycInfo、Scopus和Web of Science至2024年7月26日,最终纳入35篇文献,涵盖体外研究、动物研究、死后毒理学、临床试验和病例报告。体外研究提示硝氮烯类受体亲和力和效力常超过吗啡和芬太尼,但真实世界数据提示体内效力常低于实验发现。病例报告和临床系列提示纳洛酮仍是硝氮烯类中毒的有效解毒剂,胃肠外纳洛酮中位剂量1.20 mg成功逆转中毒表现,院前中位剂量0.8 mg;30例患者中6例因阿片效应持续接受纳洛酮输注。死后毒理学显示硝氮烯类浓度高度可变,与患者浓度重叠,难以建立致死阈值。
要点
- 硝氮烯类中毒治疗应遵循阿片类中毒指南:气道管理并给予纳洛酮。
- 胃肠外纳洛酮中位剂量1.20 mg可成功逆转硝氮烯类中毒表现,院前中位剂量0.8 mg。
- 30例患者中6例因阿片效应持续接受纳洛酮输注,该比例高于现行临床指南所反映的较短观察时间即可足够的做法。
- 硝氮烯类中毒常为多物质使用,诊断和管理复杂;所有回顾病例的分析工作中除硝氮烯类外还检出其他阿片类和其他镇静药物。
- 死后硝氮烯类浓度高度可变且与患者浓度重叠,难以建立致死阈值;部分病例仅检出硝氮烯类代谢物。
适用人群与场景
- 硝氮烯类中毒患者,包括非法药物市场暴露者、中毒和死亡病例。
- 纳入文献类型包括体外研究、动物研究、死后毒理学、临床试验和病例报告。
处置流程与药物剂量
- 硝氮烯类中毒治疗应遵循阿片类中毒指南,即进行气道管理并给予纳洛酮。
- 胃肠外纳洛酮中位剂量1.20 mg可成功逆转中毒表现;院前中位剂量0.8 mg。
- 部分患者因阿片效应持续需接受纳洛酮输注(30例中6例)。
红旗征与不能漏的情况
- 硝氮烯类中毒常涉及多物质使用(其他阿片类和其他镇静药物),使诊断和管理复杂化。
- 部分病例仅检出硝氮烯类代谢物,提示其独立药理活性或替代给药途径。
- 阿片效应持续需延长纳洛酮输注和监测。
研究设计与关键结果
- 综述共检索到1383项研究,去重后筛选557篇摘要,78篇全文筛选,最终纳入35篇。
- 体外研究提示硝氮烯类受体亲和力和效力常超过吗啡和芬太尼;真实世界数据提示体内效力常低于实验发现。
- 病例报告和临床系列提示纳洛酮仍是硝氮烯类中毒的有效解毒剂,胃肠外纳洛酮中位剂量1.20 mg成功逆转,院前中位剂量0.8 mg。
- 30例患者中6例接受纳洛酮输注,比例高于现行临床指南所反映的较短观察时间即可足够的做法。
- 死后毒理学显示硝氮烯类浓度高度可变,与患者浓度重叠,难以建立致死阈值;许多硝氮烯类死后浓度与芬太尼死后浓度相似,提示效力相似。
证据类型、等级与局限
- 证据类型:综述(纳入体外研究、动物研究、死后毒理学、临床试验和病例报告)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为硝氮烯类中毒治疗应遵循阿片类中毒指南,即进行气道管理并给予纳洛酮。
- 作者认为纳洛酮对硝氮烯类中毒有效,胃肠外中位剂量1.20 mg可成功逆转中毒表现,院前中位剂量0.8 mg。
- 作者认为 prolonged toxicity 病例提示需要延长监测和重复给予纳洛酮。
- 作者认为需要加强药物监测、提高临床认识和制定针对性减害策略,包括研发长效新型阿片拮抗剂。
- 作者认为未来研究应聚焦明确硝氮烯类受体动力学、死后重分布效应和优化纳洛酮给药方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Nitazenes are a class of potent synthetic opioids that have emerged in illicit drug markets and have been identified in combination with other opioids in cases of poisoning and fatalities. Originally developed in the 1950s, these compounds were abandoned due to their high toxicity and unfavourable therapeutic index. Recent reports indicate that nitazenes exhibit a wide range of potencies, with some exceeding that of fentanyl. Understanding the pharmacological and toxicological profiles of nitazenes is critical for public health and clinical management. This review synthesizes literature on the pharmacology, toxicity, and antagonist action of nitazenes, particularly their response to naloxone.
METHODS: A comprehensive literature review was conducted using EMBASE, Ovid MEDLINE(R), APA PsycInfo, Scopus, and Web of Science up to 26 July 2024. The main search terms used were: "nitazen*", "2-benzylbenzimidazole", "aminoisotonitazene" OR "butonitazeneor clonitazene" OR "desnitazene" OR "etodesnitazene" OR "etonitazene" OR "flunitazene" OR "isotonitazene" OR "metodesnitazene" OR "metonitazene" OR "protonitazene". Inclusion criteria encompassed in vitro and animal studies, post-mortem toxicology, clinical trials, and case reports on nitazene poisoning. Data regarding naloxone dosing in confirmed cases of nitazene poisoning were also analyzed.
RESULTS: We identified 1,383 studies, and after removing duplicates, 557 abstracts were screened. Based on the eligibility criteria, 78 articles underwent full-text screening, and 35 were included in the final review. Nitazenes exhibit variability in potency and toxicity. In vitro studies suggest that their receptor affinity and potency often surpass those of both morphine and fentanyl. Real-world data indicate that in vivo potency is often lower than experimental findings. Case reports and clinical series indicate that naloxone remains an effective antidote for nitazene poisoning. A median dose of parenteral naloxone 1.20 mg effectively reversed poisoning, with a median dose of 0.8 mg in the pre-hospital setting. However, a subset of patients received prolonged naloxone infusions due to the persistence of opioid effects. Six out of 30 patients were treated with naloxone infusions. This ratio is higher than that reflected in current clinical guidelines, in which shorter observation time is deemed sufficient. Post-mortem toxicological analyses reveal highly variable nitazene concentrations, with overlap with those concentrations found in patients. This complicates the establishment of lethal thresholds. In several cases, nitazene metabolites were detected in isolation, suggesting independent pharmacological activity or alternative routes of administration. Additionally, nitazene poisoning often involves polysubstance use, further complicating diagnosis and management.
DISCUSSION: Data on nitazene potency in humans are scarce. Nitazenes are a heterogeneous group with very high experimental potency compared to morphine. The potency in in vivo outcome studies in humans is far lower than that in in vitro studies. Post-mortem concentrations of many nitazenes are similar to the post-mortem concentrations of fentanyl and indicate a similar potency. Treatment of nitazene poisoning should follow the guidelines for opioid poisoning, that is, instituting airway management and administering naloxone. All cases reviewed had several opioids and other sedating drugs in addition to nitazenes in their analytical workup. The median parenteral dose for successful reversal of features was 1.20 mg. This finding provides reassurance that naloxone is effective for the treatment of poisoning due to nitazene as well as other potent opioids.
CONCLUSIONS: Nitazenes represent an emerging public health challenge due to their high potency, unknown pharmacokinetics, and increasing presence in illicit drug supplies. While naloxone is effective in reversing nitazene poisoning, cases of prolonged toxicity suggest the need for extended monitoring and repeated naloxone dosing. The findings of this review highlight the importance of enhanced drug surveillance, improved clinical awareness, and the development of targeted harm reduction strategies, including the potential for novel opioid antagonists with prolonged efficacy. Future research should focus on defining nitazene receptor kinetics, post-mortem redistribution effects, and optimizing naloxone administration protocols for these emerging synthetic opioids.
参考来源
- Stangeland M, Dale O, Skulberg AK, et al. Nitazenes: review of comparative pharmacology and antagonist action. Clin Toxicol (Phila). 2025. PMID: 40422647. doi:10.1080/15563650.2025.2504133
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。